Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia A — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(8 sites)
Bulgaria
Sobi Investigational Site, Sofia Germany
Sobi Investigational site, Frankfurt Sobi Investigational Site, Oldenburg Italy
Sobi Investigational Site, Milan Sobi Investigational Site, Naples Spain
Sobi Investigational Site, A Coruña Sobi Investigational Site, Valencia Sobi Investigational Site, Zaragoza Last updated February 2026